2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

被引:555
作者
Hanus, L
Abu-Lafi, S
Fride, E
Breuer, A
Vogel, Z
Shalev, DE
Kustanovich, I
Mechoulam, R
机构
[1] Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, Fac Med, IL-91120 Jerusalem, Israel
[2] Fac Sci & Technol, Chem & Chem Technol Dept, Abu Deis, West Bank, Israel
[3] Coll Judea & Samaria, Dept Behav Sci, IL-88437 Ariel, Israel
[4] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel
[5] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel
[6] Hebrew Univ Jerusalem, Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel
关键词
D O I
10.1073/pnas.061029898
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Two types of endogenous cannabinoid-receptor agonists have been identified thus far. They are the ethanolamides of polyunsaturated fatty acids-arachidonoyl ethanolamide (anandamide) is the best known compound in the amide series-and 2-arachidonoyl glycerol, the only known endocannabinoid in the ester series. We report now an example of a third, ether-type endocannabinoid, 2-arachidonyl glyceryl ether (noladin ether), isolated from porcine brain. The structure of noladin ether was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and was confirmed by comparison with a synthetic sample. It binds to the CB1 cannabinoid receptor (K-i = 21.2 +/- 0.5 nM) and causes sedation, hypothermia, intestinal immobility, and mild antinociception in mice. It binds weakly to the CB2 receptor (K-i > 3 muM).
引用
收藏
页码:3662 / 3665
页数:4
相关论文
共 27 条
[1]   Cannabinoid receptors and their endogenous agonist, anandamide [J].
Axelrod, J ;
Felder, CC .
NEUROCHEMICAL RESEARCH, 1998, 23 (05) :575-581
[2]  
BARNES PY, 1989, PLATELET ACTIVATING
[3]   Cytotoxic etherphospholipid analogues [J].
Berkovic, D .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1998, 31 (04) :511-517
[4]  
Chang Y. C., 1973, BIOCHEM PHARMACOL, V22, P3099
[5]   A NOVEL PROBE FOR THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
BREUER, A ;
SHESKIN, T ;
JARBE, TUC ;
EISEN, MS ;
MECHOULAM, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (11) :2065-2069
[6]   ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
HANUS, L ;
BREUER, A ;
PERTWEE, RG ;
STEVENSON, LA ;
GRIFFIN, G ;
GIBSON, D ;
MANDELBAUM, A ;
ETINGER, A ;
MECHOULAM, R .
SCIENCE, 1992, 258 (5090) :1946-1949
[7]   PHARMACOLOGICAL ACTIVITY OF THE CANNABINOID RECEPTOR AGONIST, ANANDAMIDE, A BRAIN CONSTITUENT [J].
FRIDE, E ;
MECHOULAM, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 231 (02) :313-314
[8]   2 NEW UNSATURATED FATTY-ACID ETHANOLAMIDES IN BRAIN THAT BIND TO THE CANNABINOID RECEPTOR [J].
HANUS, L ;
GOPHER, A ;
ALMOG, S ;
MECHOULAM, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (20) :3032-3034
[9]   Miltefosine - The long-awaited therapy for visceral leishmaniasis? [J].
Herwaldt, BL .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (24) :1840-1842
[10]   Cannabinoid receptors and immunity [J].
Klein, TW ;
Newton, C ;
Friedman, H .
IMMUNOLOGY TODAY, 1998, 19 (08) :373-381